Achieved Statistical Significance with Up to 48% Slowing of Clinical Progression on UMSARS Rating Scale - MELBOURNE, Australia and SAN FRANCISCO, Jan. 30, 2025 (GLOBE NEWSWIRE) -- Alterity ...

Alterity Therapeutics (NASDAQ: ATHE) shares moved up at warp-speed Thursday, on announcing positive topline results from the ATH434-201 randomized, double-blind, placebo-controlled Phase 2 clinical ...

God And Parkinson's Book Edward G. Palmer, the author of this DIY healing blueprint, found himself facing Parkinson's disease. His personal ...

Stop the Spread. Injecting saline into mouse kidneys did not affect the left or right substantia nigra (top). Injecting fibrils of α-synuclein ablated about half of the dopaminergic neurons (middle ...

This has the capacity to connect generations in a caring, helping way, which you can’t do artificially. I have to admit, I did not foresee that in this regard.” And with that, Española Glove Works was ...

HighlightsTopline data for ATH434-201 randomized, double-blind Phase 2 clinical trial on track for expected release by early February ...

A major research breakthrough on Parkinson's disease revealed that an already FDA-approved cancer drug could help stem the ...

A radically upgraded Parkinson’s treatment which zaps the brain to control its debilitating tremors has been rolled out on the NHS. Known as adaptive deep brain stimulation, the implant ...

Nonmotor symptoms may appear during the course of Parkinson's disease, complicating the advanced phase in particular, but are also common in the premotor phase of Parkinson's disease. The ...

Formerly believed to predominantly affect Caucasians, new research indicates that MS actually may hit Blacks the hardest.

Parkinson's disease is a progressive disorder that develops when the brain cells that produce dopamine (a chemical involved in movement) stop working or die. When this happens, symptoms like slowed ...